Haemonetics Corporation

HAE.US
Healthcare · Medical Devices
82.54
+2.63 (+3.29%)
USD · NYSE

Company Information

Company Name
Haemonetics Corporation
Sector
Healthcare
Industry
Medical Devices
Exchange
NYSE
ISIN: US4050241003
CIK: 0000313143
CUSIP: 405024100
Currency: USD
Full Time Employees: 3,009
Phone: 781 848 7100
Fiscal Year End: March
IPO Date: May 09, 1991
Description:

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Address:

125 Summer Street, Boston, MA, United States, 02110

People

Directors & Officers

Name Title Year Born
Mr. Christopher A. Simon CEO, President & Director 1964
Mr. James C. D'Arecca CPA CFO, Executive VP & Financial Officer 1971
Mr. Frank W. Chan Ph.D. Executive VP & COO 1970
Ms. Michelle L. Basil Esq., J.D. Executive VP, General Counsel & Secretary 1973
Mr. Roy Galvin Executive VP & Chief Commercial Officer 1970
Ms. Farris Maryanne E. Maunsell VP, Chief Accounting Officer & Principal Accounting Officer 1976
Ms. Olga Guyette Senior Director of Investor Relations NA
Mr. Rajeev Varma Senior Vice President of Strategy & Corporate Development NA
Ms. Laurie A. Miller Senior VP & Chief Human Resources Officer 1974
Dr. Jan Hartmann M.D. Senior VP & Chief Medical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jul 26, 2024 Stewart W Strong N/A Sale 4.31K $91.15 $393.04K
Jul 11, 2024 Anila Lingamneni N/A Sale 2.14K $90.00 $192.24K
May 29, 2024 Michelle L Basil N/A Sale 12.99K $88.08 $1.14M
May 29, 2024 Stewart W Strong N/A Sale 8.86K $87.53 $775.25K
May 20, 2024 Josep Llorens N/A Sale 987.00 $95.08 $93.84K
May 20, 2024 Stewart W Strong N/A Sale 686.00 $95.11 $65.25K
May 17, 2024 Josep Llorens N/A Sale 822.00 $94.82 $77.94K
May 16, 2024 Stewart W Strong N/A Sale 733.00 $96.04 $70.40K
May 06, 2024 Anila Lingamneni N/A Sale 2.31K $95.00 $218.98K
Sep 12, 2023 Stewart W Strong N/A Sale 228.00 $90.65 $20.67K
Sep 11, 2023 Anila Lingamneni N/A Sale 2.31K $90.00 $207.45K
Jul 18, 2023 Josep Llorens N/A Sale 4.93K $90.00 $443.52K
May 30, 2023 Anila Lingamneni N/A Sale 2.30K $83.33 $191.99K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.62M Mar 31, 2026 12.37% $0.01 -3.45%
Vanguard Group Inc 4.76M Dec 31, 2025 10.48% $0.01 -1.52%
Neuberger Berman Group LLC 3.56M Mar 31, 2026 7.84% $0.15 -7.88%
AQR Capital Management LLC 3.36M Mar 31, 2026 7.39% $0.09 6.12%
Vanguard Portfolio Management, LLC 2.56M Mar 31, 2026 5.63% $0.01 0.00%
Vanguard Capital Management, LLC 2.09M Mar 31, 2026 4.60% $0.00 0.00%
State Street Corp 1.77M Mar 31, 2026 3.90% $0.00 2.49%
Arrowstreet Capital Limited Partnership 1.38M Mar 31, 2026 3.04% $0.04 0.21%
Dimensional Fund Advisors, Inc. 1.33M Mar 31, 2026 2.92% $0.02 21.33%
River Road Asset Management, LLC 1.29M Jun 30, 2026 2.83% $1.07 -3.19%
FMR Inc 1.28M Mar 31, 2026 2.81% $0.00 -3.84%
Geode Capital Management, LLC 1.22M Mar 31, 2026 2.68% $0.00 2.04%
North Peak Capital Management, LLC 998.95K Mar 31, 2026 2.20% $9.36 -9.43%
The Goldman Sachs Group Inc 952.82K Mar 31, 2026 2.10% $0.01 -22.32%
Allspring Global Investments Holdings, LLC 890.22K Mar 31, 2026 1.96% $0.08 -5.27%
Royal Bank of Canada 857.97K Mar 31, 2026 1.89% $0.01 -11.33%
Fort Washington Investment Advisors Inc 830.93K Jun 30, 2026 1.83% $0.31 -1.20%
Invenomic Capital Management, LP 664.73K Mar 31, 2026 1.46% $1.72 0.00%
T. Rowe Price Investment Management,Inc. 597.16K Mar 31, 2026 1.31% $0.02 -66.67%
Northern Trust Corp 579.31K Mar 31, 2026 1.27% $0.00 0.27%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Mid-Cap ETF 1.58M 3.48% ▼ 0.44% Jun 30, 2026
2 Neuberger Genesis Inv 1.49M 3.28% ▲ 22.11% Jun 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 1.44M 3.17% ▼ 2.75% Jun 30, 2026
4 iShares Russell 2000 ETF 1.23M 2.72% ▲ 0.60% Jun 30, 2026
5 Vanguard Small Cap Index 1.04M 2.29% ▼ 2.43% Jun 30, 2026
6 Fort Washington Small Company Equity 811.85K 1.79% ▲ 21.16% Mar 31, 2026
7 Small Company Equity - FTWA 811.85K 1.79% ▲ 0.00% Mar 31, 2026
8 Touchstone Small Company A 614.82K 1.35% ▲ 0.30% Jun 30, 2026
9 Ariel Fund Investor 573.67K 1.26% ▲ 0.00% Jun 30, 2026
10 AQR Long-Short Equity I 555.16K 1.22% ▲ 1.44% Mar 31, 2026

Financial Highlights

Market Cap: $3.63B
EBITDA: $357.15M
P/E Ratio: $38.42
PEG Ratio: $1.26
Book Value: $17.60
Earnings/Share: $2.08
Profit Margin: 7.29%
Operating Margin: 13.88%
ROA (TTM): 6.49%
ROE (TTM): 12.03%
Revenue (TTM): $1.33B
Revenue/Share (TTM): $28.28
Earnings Growth (YOY): 28.40%
Revenue Growth (YOY): 4.80%

Valuation Metrics

Enterprise Value: $4.56B
Trailing P/E: 38.42
Forward P/E: 15.08

Shares Statistics

Shares Outstanding: 45.45M
Shares Float: 44.86M
% Insiders: 122.00%
% Institutions: 11,023.50%
Short % Float: 8.06%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$1.33B
Cost of Goods Sold
adjust
$-590.44M
Gross Profit
subtotal
$743.59M
SG&A
adjust
$-442.42M
R&D
adjust
$-59.77M
Operating Income
subtotal
$241.40M
Other / Non-Operating Items
adjust
$-144.09M
Net Income
subtotal
$97.31M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HAE.US!